Gilead published new data on its antiviral drug remdesivir that shows it reduced the risk of death for severely sick coronavirus patients.
The analysis also found that 74.4% of patients who received treatment with remdesivir recovered by day 14 compared with 59% of patients who received standard care alone."We are working to broaden our understanding of the full utility of remdesivir," Gilead's Chief Medical Officer Dr. Merdad Parsey said in a statement.
In late April, the National Institute of Allergy and Infectious Diseases released preliminary results from its own study of remdesivir that showed patients who took remdesivir usually recovered after 11 days, four days faster than those who didn't take the drug. However, the study did not find any statistically significant reduction in the risk of death among patients treated with remdesivir.
NIAID's findings led the Food and Drug Administration to issue an emergency use authorization for remdesivir, allowing doctors to use the drug on hospitalized Covid-19 patients. However, the drug has not undergone the same level of review as fully FDA-authorized drugs. There are still no FDA-authorized drugs to treat Covid-19.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead Testing Inhaled Form Of Remdesivir That Could Be Used To Treat Covid-19 Outside HospitalGilead is launching a phase 1 clinical trial of an inhaled version of remdesivir, a drug used to treat Covid-19, that could be administered to patients outside of the hospital
Read more »
Stocks Cut Losses After Gilead Says Remdesivir Coronavirus Treatment Reduces Risk Of DeathThe market opened flat as investors weigh a recent spike in new cases with positive vaccine news.
Read more »
Gilead says remdesivir coronavirus treatment reduces risk of death
Read more »
A new Gilead analysis indicates remdesivir can reduce death but company says finding 'requires confirmation'Shares of Gilead Sciences Inc. undefined gained 2.0% in premarket trading on Friday after the drugmaker disclosed findings from a new analysis of previously...
Read more »
Gilead begins testing inhalable form of remdesivir for COVID-19Gilead Sciences Inc said on Wednesday it has started an early-stage study of its antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
Read more »
Gilead says remdesivir coronavirus treatment reduces risk of death
Read more »